Precision Biologics Presents Preclinical Data on Novel PB-223 ADC Targeting Truncated Core-2 Glycans in Solid Tumors
核心洞察
Precision Biologics (搜索)' CEO Philip M. Arlen presented preclinical data on PB-223 ADC (搜索) (PB-vcMMAE-5 (搜索)), a novel antibody-drug conjugate targeting truncated core-2 O-glycans (搜索) in solid tumors (搜索).
The company reported complete tumor eradication in animal xenograft models with minimal toxicity observed in blood and tissue analysis across several human cancer (搜索) types.
The target is found on a broad variety of human solid tumors (搜索) but not on healthy tissue, providing a strong rationale for advancing to clinical trials.
Precision Biologics (搜索), Inc. unveiled compelling preclinical data for its novel antibody-drug conjugate PB-223 ADC (搜索) (PB-vcMMAE-5 (搜索)) at the 6th ACE Drug Discovery Summit in London, marking a significant milestone in the development of targeted cancer (搜索) therapeutics. CEO Philip M. Arlen, MD, presented the first comprehensive public overview of the drug's efficacy data, demonstrating promising anti-tumor activity across multiple solid tumor types.
Novel Targeting Mechanism Shows Broad Applicability
The PB-223 ADC (搜索) targets truncated core-2 O-glycans (搜索), a unique molecular signature found on various human solid tumors (搜索) but absent from healthy tissue. This selective targeting mechanism enables the drug to achieve maximum anti-tumor response while minimizing toxicity in preclinical studies. According to Arlen, "The exquisite sensitivity and specificity of our recently developed mAb enables maximum anti-tumor response to our PB-223 ADC with minimal toxicity in the preclinical animal studies."
The company's research demonstrates that the target is present on a broad variety of human solid tumors (搜索), suggesting potential applications across multiple cancer (搜索) indications. This broad targeting capability could position PB-223 ADC (搜索) as a versatile therapeutic option in the oncology pipeline.
Preclinical Efficacy Demonstrates Complete Tumor Eradication
The most striking results from Precision Biologics (搜索)' preclinical program show complete tumor eradication in animal xenograft models using human tumor samples. These studies evaluated the drug's performance across several human cancer (搜索) types, with comprehensive safety monitoring through blood and tissue analysis revealing minimal toxicity profiles.
"We're excited to discuss PB-223 ADC (搜索) with the scientific community, to share compelling preclinical data with several human tumor types, showing animal xenograph human tumor models resulting in complete tumor eradication with minimal toxicity observed in blood and tissue analysis," Arlen stated during the presentation.
Clinical Development Pathway
The favorable preclinical safety and efficacy profile has provided Precision Biologics (搜索) with a strong rationale to advance PB-223 ADC (搜索) into clinical trials. The company's confidence in the drug's clinical potential stems from the combination of tumor-specific targeting and the demonstrated therapeutic window observed in animal studies.
While preliminary data was previously presented at poster sessions during the Society for the Immunotherapy of Cancer (搜索) (SITC) and American Association for Cancer Research Ovarian Cancer (AACR-Ovarian) meetings, the London presentation represented the first comprehensive public discussion of the complete dataset.
ADC Technology Platform
PB-223 ADC (搜索) utilizes the vcMMAE-5 payload system, a well-established cytotoxic component in the antibody-drug conjugate field. The drug's design combines the company's proprietary monoclonal antibody targeting truncated core-2 glycans (搜索) with this proven cytotoxic payload, creating a targeted therapeutic approach designed to maximize tumor cell killing while sparing healthy tissue.